Cargando…

A bias‐free, automated planning tool for technique comparison in radiotherapy ‐ application to nasopharyngeal carcinoma treatments

In this study a novel, user‐independent automated planning technique was developed to objectively compare volumetric‐modulated arc therapy (VMAT) and intensity‐modulated radiotherapy (IMRT) for nasopharyngeal carcinoma planning, and to determine which technique offers a greater benefit for parotid‐s...

Descripción completa

Detalles Bibliográficos
Autores principales: Boylan, Christopher, Rowbottom, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711248/
https://www.ncbi.nlm.nih.gov/pubmed/24423853
http://dx.doi.org/10.1120/jacmp.v15i1.4530
Descripción
Sumario:In this study a novel, user‐independent automated planning technique was developed to objectively compare volumetric‐modulated arc therapy (VMAT) and intensity‐modulated radiotherapy (IMRT) for nasopharyngeal carcinoma planning, and to determine which technique offers a greater benefit for parotid‐sparing and dose escalation strategies. Ten patients were investigated, with a standard prescription of three dose levels to the target volumes (70, 63, and 56 Gy), using a simultaneous integrated boost in 33 fractions. The automated tool was used to investigate three planning strategies with both IMRT and VMAT: clinically acceptable plan creation, parotid dose sparing, and dose escalation. Clinically acceptable plans were achieved for all patients using both techniques. For parotid‐sparing, automated planning reduced the mean dose to a greater extent using VMAT rather than IMRT (17.0 Gy and 19.6 Gy, respectively, [Formula: see text]). For dose escalation to the mean of the main clinical target volume, neither VMAT nor IMRT offered a significant benefit over the other. The OAR‐limiting prescriptions for VMAT ranged from 84‐98 Gy, compared to 76‐110 Gy for IMRT. Employing a user‐independent planning technique, it was possible to objectively compare VMAT and IMRT for nasopharyngeal carcinoma treatment strategies. VMAT offers a parotid‐sparing improvement, but no significant benefit was observed for dose escalation to the primary target. PACS numbers: 87.55.D‐, 87.55.kd